Retatrutide vs Mounjaro: What the Data Says About the 'Stronger Than' Claim

Retatrutide keeps popping up in headlines, and many of them say it's 'stronger than Mounjaro.' Before you accept that, it helps to know what the research actually compared. Retatrutide is an experimental medicine from Eli Lilly that acts on three hormone receptors: GIP, GLP-1, and glucagon. Tirzepatide, sold as Mounjaro, acts on two of them, GIP and GLP-1. The Mounjaro label describes it as a dual GIP and GLP-1 receptor agonist. That difference in mechanism is real, but it doesn't tell you which drug produces more weight loss in people.

Where the 'stronger than Mounjaro' claim comes from

The comparison doesn't come from a head-to-head study. No trial has randomized people to retatrutide and tirzepatide and measured the difference between them. Instead, the claim lines up numbers from separate trials, each with its own participants, length, and design. Two figures side by side look like a comparison, but it's closer to comparing race times run on different courses.

Readers want a shortcut, and that's understandable. There are many GLP-1 options, prices are high, and people want a quick answer about which one works best. A bold headline delivers that answer in seconds, so it spreads fast, even when the fine print is missing.

What the phase 2 data actually measured

The main source for retatrutide's weight loss numbers is a phase 2 trial published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues. The study ran for 48 weeks and tested retatrutide at 1 mg, 4 mg, 8 mg, and 12 mg against placebo.

At the highest dose, 12 mg, the mean percent change in body weight from baseline at week 48 was 24.2%. The placebo group's mean change was 2.1%. The word 'mean' matters, because the figure is an average, so some people lost much more and some lost much less. The primary endpoint was the percent change in body weight from baseline at week 48, and the paper reports the raw change for each arm.

You can also do a simple subtraction. Taking 24.2% minus 2.1% gives a difference of 22.1 percentage points. That's my arithmetic, not a figure the paper states, and it shows how much of the loss goes beyond what happens with placebo. Check the tables in the paper for the exact values and any adjusted analyses.

Enrollment was narrower than many readers assume. Participants had obesity (a BMI of 30 or higher) or overweight (27 or higher) with at least one weight-related condition, and the trial excluded people with type 2 diabetes. That population doesn't match every patient who might take these drugs, so keep it in mind when you compare results.

Why cross-trial comparisons mislead

Trial length alone can change the picture. SURMOUNT-1, the tirzepatide trial published in NEJM in 2022, ran for 72 weeks. The retatrutide phase 2 ran for 48. Weight curves don't always flatten at the same point, so a week-48 number and a week-72 number answer different questions. SURMOUNT-1 reported a mean change of 20.9% at 72 weeks with the 15 mg dose, but that's a different trial with different people.

Baseline characteristics matter too. People who start heavier often lose more in absolute kilograms, and percentages can shift depending on who enrolled. Dosing schedules and escalation plans also differ between studies. Compare the baseline tables in each paper before you decide the populations are similar.

The analysis method can change the headline as well. A treatment-regimen approach counts participants whether or not they stayed on the drug. An on-treatment analysis looks only at data collected while people were still taking it. Both answer legitimate questions, but the same drug can look better or worse depending on which one gets quoted. Compare each paper's estimand definition and discontinuation rates before drawing conclusions. The OzemNews breakdown of trial design walks through these differences in plain language.

Tolerability and side effect signals

Like other incretin drugs, retatrutide's most common complaints were gastrointestinal, including nausea and diarrhea. The tirzepatide label describes gradual dose escalation as a way to lower gastrointestinal reactions, and that approach is what prescribers typically follow with this class. Many people find the early weeks hardest, which is one reason doses usually start low.

The phase 2 paper also reported dysesthesia, which the authors describe as abnormal skin sensations such as tingling or burning. It appeared more often in retatrutide arms than in placebo. The exact frequencies are in the adverse event tables of the NEJM paper, so check those rather than relying on rounded summaries from news stories.

Heart rate increases were another signal. The authors observed higher heart rates with retatrutide, and they said this would need monitoring in larger, longer studies. They treat it as something to study, not as proof of harm.

When you compare discontinuation due to adverse events, match the data type. Look at the percentage of participants who stopped because of side effects in the retatrutide arms of the phase 2 paper, then compare it with the tirzepatide arms in SURMOUNT-1. Confirm whether each number refers to all randomized participants or only a subgroup. The Mounjaro label lists adverse reactions and their frequencies, which makes a useful cross-check.

Regulatory status and access in Brazil

As of the latest information we could verify, retatrutide is not approved for prescription in Brazil or anywhere else. Confirm this on the day you read it, because regulatory status can change quickly. Lilly's phase 3 program, called TRIUMPH, includes several studies. Search ClinicalTrials.gov for 'retatrutide' to see the registered identifiers, current status, and expected completion dates.

That gap creates room for sellers who claim to offer retatrutide. Gray-market products, unregistered pens, and compounding claims carry real risk, because nobody can verify what's in the vial, the dose, or how it was made. Press reports have described seizures of unregistered pens at Brazilian borders, but check the official record before relying on any specific case.

Anvisa's consultation portal lets you search registered medicines by name. If a product doesn't appear there, treat that as a warning sign, and talk to a licensed prescriber about options that are actually approved. For ongoing coverage, our reporting on Brazil's regulatory updates at OzemNews tracks these changes as they happen.

How to read the headline before you trust it

Start with four questions. Is the comparison head-to-head? What population was studied? How long did the trial run? Who sponsored it? Lilly sponsors both the retatrutide and tirzepatide programs. That doesn't make the data wrong, but it's a good reason to read the methods closely.

Next, ask what the number represents. Is it a mean, a median, or a responder rate, meaning the share of people who hit a specific threshold? Does it include everyone who started, or only those who finished? An average can hide a wide range of individual results, so look at the spread when the paper reports it.

Weight regain deserves attention too. Regain after stopping incretin therapy varies by drug and by study design, so don't assume one pattern applies across the board. Check the regain data in the trial publications themselves, since press summaries often drop the details that matter.

If you want to go deeper, start with previous OzemNews coverage of clinical data, then open the primary sources yourself: the NEJM articles, the ClinicalTrials.gov entries, and the Mounjaro label on Drugs@FDA.

These medicines can help with weight management when they're used under medical supervision, and that context matters most. They are not a cure, and they don't replace a prescriber's guidance on whether a specific drug fits your health history. If retatrutide reaches the market, it will deserve the same careful reading as every other option.

FAQ

Is retatrutide stronger than tirzepatide?

No head-to-head trial has compared them directly, so current evidence can't settle which one produces more weight loss. Cross-trial numbers differ in length, population, and analysis method.

Is retatrutide approved in Brazil?

Not as far as we could verify. Search the Anvisa registry before trusting any seller who claims otherwise.

When will the retatrutide phase 3 results be available?

The TRIUMPH studies are registered on ClinicalTrials.gov with expected completion dates. Results depend on each trial finishing and being published.

Can I buy retatrutide without a prescription?

No approved option is available that way. Products sold through informal channels without Anvisa registration may contain unknown ingredients or doses. Talk to a licensed prescriber about approved options.

Sources

• Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, phase 2 trial, New England Journal of Medicine, 2023
• Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022
• Mounjaro (tirzepatide) prescribing information, Drugs@FDA, U.S. Food and Drug Administration
• ClinicalTrials.gov search results for retatrutide, U.S. National Library of Medicine
• Consulta de medicamentos registrados, Anvisa